7th Jun 2005 10:17
Tissue Science Laboratories PLC07 June 2005 7 June 2005 Tissue Science Laboratories plc ('TSL' or 'the Company') Grant of Share Options to Directors Tissue Science Laboratories plc (LSE: TSL), the medical devices companyspecialising in human tissue replacement and repair products derived fromporcine dermis, announces today that share options have been granted to threeDirectors: Martin Hunt, Chief Executive 100,000 David Jennings, Finance Director 80,000 Steve Bloor, Technical Director 85,000 Date of grant: 7 June, 2005 Period during which exercisable: minimum 5 year vesting period Description of shares involved: 265,000 of ordinary shares Exercise price: £1.70 -Ends- For further information, please contact: TSL plc Tel: 01252 369603Martin Hunt, Chief Executive Hogarth Partnership Limited Tel: 020 7357 9477Melanie Toyne-Sewell / Kate Catchpole Notes to Editors Background on TSL Founded in 1995, with headquarters in Aldershot, Hampshire, TSL is a medicaltechnology company specialising in tissue repair and replacement with aproprietary sheet product, derived from porcine dermis, called Permacol(R). TSLhas launched successfully different formulations of the product and built adevelopment pipeline that addresses the large and fast growing surgical implantmarket. The Company floated in November 2001 and is listed on the AlternativeInvestment Market (LSE: TSL). TSL has a family of products based on the samecore technology. Each product has been adapted, with unique properties, to makeit suitable for use in different applications, including urology/gynaecology,complex and recurrent hernia repair, shoulder rotator cuff repair and head andface repair and reconstruction. The Company has signed distribution agreementswith CR Bard Inc (urology/gynaecology - worldwide), Zimmer Inc (orthopaedic -worldwide) and Porex Surgical Inc (head & ace-US and Canada). Further variationsof the sheet and injectable forms of Permacol(R) are being developed. Background on Permacol(R) Permacol(R) was developed at Dundee University over a 20 year time period andhas been patented worldwide. The key to the Permacol(R) concept lies in itcollagen Technology which uses non-reconstituted porcine dermal collagen, verysimilar in structure to human tissue. Non-collagenous material, except elastin,is removed by the TSL manufacturing process. The remaining collagen, whichretains its original 3 D structural architecture, is stabilised by a patentedcross-linking process. The result is a non-reconstituted, non-allergenic,collagen implant which is resistant to biodegradation attack, is recognised andaccepted by the body, and is able to provide a long-term support for thein-growth of new tissue and its associated blood supply. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
TSL.L